Trivium Point Advisory LLC Has $4.74 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Trivium Point Advisory LLC reduced its stake in Thermo Fisher Scientific by 9.1%, now holding 9,530 shares valued at approximately $4.74 million.
• Multiple hedge funds modified their positions in the company, with Mondrian Investment Partners LTD increasing its stake by 146.1% during the first quarter.
• Thermo Fisher Scientific reported earnings of $5.36 per share for the most recent quarter, surpassing expectations and showing a 2.9% year-over-year revenue growth.

Trivium Point Advisory LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,530 shares of the medical research company's stock after selling 956 shares during the period. Trivium Point Advisory LLC's holdings in Thermo Fisher Scientific were worth $4,742,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Inspire Trust Co. N.A. raised its holdings in shares of Thermo Fisher Scientific by 18.4% during the first quarter. Inspire Trust Co. N.A. now owns 5,800 shares of the medical research company's stock worth $2,886,000 after purchasing an additional 900 shares during the period. Vestmark Advisory Solutions Inc. increased its holdings in shares of Thermo Fisher Scientific by 99.7% in the 1st quarter. Vestmark Advisory Solutions Inc. now owns 14,491 shares of the medical research company's stock worth $7,211,000 after acquiring an additional 7,235 shares during the period. Harfst & Associates Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth about $602,000. Sit Investment Associates Inc. increased its holdings in shares of Thermo Fisher Scientific by 1.1% in the 1st quarter. Sit Investment Associates Inc. now owns 24,823 shares of the medical research company's stock worth $12,352,000 after acquiring an additional 276 shares during the period. Finally, Mitsubishi UFJ Asset Management UK Ltd. acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $149,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 18,400 shares of company stock worth $8,345,792. Insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on TMO. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 10th. Barclays raised their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Robert W. Baird raised their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada cut their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Stock Up 1.0%

TMO traded up $4.92 during midday trading on Friday, hitting $489.96. 2,462,453 shares of the company's stock traded hands, compared to its average volume of 3,069,315. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a market cap of $185.01 billion, a PE ratio of 28.34, a price-to-earnings-growth ratio of 2.61 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock's fifty day simple moving average is $434.83 and its 200-day simple moving average is $460.05.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the firm posted $5.37 earnings per share. The company's quarterly revenue was up 2.9% compared to the same quarter last year. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.